Crossject has developed a deep pipeline of products that are based on its proprietary needle-free injection system, ZENEO, across a variety of indications. The benefits of ZENEO include no need for needles, as well as a simple and quick (~1/10th of a second) delivery of the drug. Its first commercial product, ZENEO Methotrexate for rheumatoid arthritis, should reach the market in 2017. We value the company at €11.96 per share, which is based on the value of four of its nearer-term disclo
13 Jun 2016
Making injections simple, quick and needle-free
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Making injections simple, quick and needle-free
Crossject SA (ALCJ:PAR) | 0 0 (-3.4%) | Mkt Cap: 38.7m
- Published:
13 Jun 2016 -
Author:
Maxim Jacobs -
Pages:
12
Crossject has developed a deep pipeline of products that are based on its proprietary needle-free injection system, ZENEO, across a variety of indications. The benefits of ZENEO include no need for needles, as well as a simple and quick (~1/10th of a second) delivery of the drug. Its first commercial product, ZENEO Methotrexate for rheumatoid arthritis, should reach the market in 2017. We value the company at €11.96 per share, which is based on the value of four of its nearer-term disclo